Collegium Pharmaceutical Q3 Earnings Call Highlights

Collegium Pharmaceutical reported Q3 revenue of $138M from its pain portfolio, with BELBUCA sales at $57.7M, XTAMPZA ER at $45.8M, and NUCYNTA at $30.8M. The company expects AZSTARYS prescription growth to accelerate in 2027 and reaffirmed its 2026 revenue forecast of $825M-$855M. It plans a $50M share repurchase and has $100M remaining under its authorization.

Original reporting
Published Nov 5, 2026, 3:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 3:23 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Collegium Pharmaceutical Q3 Earnings Call Highlights — source image
Decision brief

The 30-second read

$COLLNeutralMed
01

Why it matters

The mixed earnings results introduce both downside from pain‑portfolio weakness and upside from the share buyback and AZSTARYS growth outlook.

02

Market read

Earnings release offers actionable data on revenue trends, margin pressure, and capital allocation, influencing short‑term price dynamics.

03

What to watch

Potential upside from AZSTARYS growth and JORNAY PM contributions not fully reflected yet.

Relevance 7/10Novelty 7/10Timing: post‑earnings today

Background

Collegium Pharmaceutical provided its Q3 earnings call highlights, including product sales, gross‑to‑net metrics, guidance, cash flow, debt levels, and a planned share repurchase.

Company-level read

Ticker impact

$COLLNeutralHigh confidence
Context

Q3 earnings release with revenue, margin, guidance and share repurchase details provides fresh material for the stock.

Expected impact

likely pressure as market prices in weaker pain sales despite buyback announcement

Evidence & confidence

Revenue decline in key products and higher gross-to-net deductions suggest margin pressure, while a $50M accelerated repurchase offers support.

Market effects

Pain‑management pharma sector may see scrutiny on generic competition and margin pressure.

U.S. specialty pharma stocks could experience modest volatility.

Limited to U.S. investors; no broader macro impact.

Counterpoint

Buyback could signal confidence; price may rally if investors focus on capital return rather than sales decline.

Key entities

  • Collegium Pharmaceutical

    Specialty pharma firm reporting Q3 results.

  • Karan Karnani

    CEO providing commentary on product outlook.

  • Colleen Tupper

    CFO discussing financial metrics.

Related articles

$COLLMedAI 8/10

Collegium Pharmaceutical Earnings Call Highlights ADHD Growth

Collegium Pharmaceutical (COLL) reported Q3 record revenue of $216.3M, up 3% YoY, driven by ADHD products (36% of total revenue). Jornay PM grew 24% YoY to $52M-$59.5M, while Azstarys saw 2% prescription growth. Pain portfolio revenue declined 9% YoY. Adjusted EBITDA fell 9% to $121.6M. The company reaffirmed 2026 guidance, expecting flat adjusted EBITDA.

$COLLMed

Jefferies cuts Collegium Pharmaceutical stock price target on pain business concerns

Jefferies reduced its price target for Collegium Pharmaceutical (COLL) to $35 from $51, citing concerns about its pain business. The stock is down 45.66% year-to-date. The company reported Q3 2026 earnings, beating EPS estimates but meeting revenue expectations. Management plans to continue share buybacks and deleverage. Jefferies expects modest EBITDA growth by 2027, with ADHD business growth offsetting pain segment declines.

$COLLMed

Collegium (COLL) Q3 2026 Earnings Call Transcript

Collegium (COLL) reported Q3 2026 net revenue of $216.3M, up 3% YoY. Jornay PM prescriptions grew 16% YoY, generating $59.5M in revenue. Azstarys revenue was $26.5M, with prescriptions up nearly 2% YoY. The company reaffirmed full-year guidance and announced a $50M share repurchase program.

$COLLLow

Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance

COLLEGIUM PHARMACEUTICAL, INC (COLL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Collegium Reports Third Quarter 2026 Financial Results; Reaffirms 2026 Guidance – Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM ® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Genera